Carnitine palmitoyltransferase 1C contributes to progressive cellular senescence. by Wang, Yongtao et al.
UC Davis
UC Davis Previously Published Works
Title
Carnitine palmitoyltransferase 1C contributes to progressive cellular senescence.
Permalink
https://escholarship.org/uc/item/0fc4j7ps
Journal
Aging, 12(8)
ISSN
1945-4589
Authors
Wang, Yongtao
Yu, Tao
Zhou, Yanying
et al.
Publication Date
2020-04-14
DOI
10.18632/aging.103033
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
 www.aging-us.com 6733 AGING 
INTRODUCTION 
 
A commonly used stable transfection manipulation for 
an exogenous gene with a selectable marker that 
remains in the genome of eukaryotic cells and their 
daughter cells is highly desirable [1]. Cells then remain 
alive and can be further cultivated under selective 
stress with passaging. However, stable transfection 
manipulation induces progressive cellular senescence 
phenotypes, leading to a common problem in cell 
culture. The underlying mechanisms of stable 
transfection-induced cellular senescence remain poorly 
understood. As reported in our previous study [2], 
extended passaging of PANC-1 cells were triggered 
into a replicative senescence process with low CPT1C 
levels. Low CPT1C expression further caused 
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ABSTRACT 
 
Stable transfection manipulation with antibiotic selection and passaging induces progressive cellular senescence 
phenotypes. However, the underlying mechanisms remain poorly understood. This study demonstrated that 
stable transfection of the empty vector induced PANC-1 cells into cellular senescence. Metabolomics revealed 
several acylcarnitines and their upstream regulatory gene, carnitine palmitoyltransferase 1C (CPT1C) involved in 
fatty acid β-oxidation in mitochondria, were strikingly decreased in senescent PANC-1 cells. Low CPT1C expression 
triggered mitochondrial dysfunction, inhibited telomere elongation, impaired cell survival under metabolic stress, 
and hindered the malignance and tumorigenesis of senescent cells. On the contrary, mitochondrial activity was 
restored by CPT1C gain-of-function in senescent vector PANC-1 cells. PPARα and TP53/CDKN1A, crucial signaling 
components in cellular senescence, were downregulated in senescent PANC-1 cells. This study identifies CPT1C as 
a key regulator of stable transfection-induced progressive PANC-1 cell senescence that inhibits mitochondrial 
function-associated metabolic reprogramming. These findings confirm the need to identify cell culture alterations 
after stable transfection, particularly when cells are used for metabolomics and mitochondria-associated studies, 
and suggest inhibition of CPT1C could be a promising target to intervene pancreatic tumorigenesis. 
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mitochondria dysfunction-associated metabolic 
reprogramming and impaired malignancy in senescent 
replicative PANC-1 cells. More importantly, 
knockdown of CPT1C in cancer cells induced 
mitochondrial dysfunction, senescence-like growth 
suppression and cellular senescence and further 
suppressed malignancy and tumorigenesis in vivo and 
xenograft tumor growth in situ. On the contrary, the 
gain-of-function of CPT1C reversed PANC-1 cell 
senescence and enhanced mitochondrial function. 
CPT1C was hence confirmed as a novel biomarker for 
mitochondrial dysfunction-associated cellular 
senescence [2]. Recently, microRNA-1291 and its 
mimic empty vector pCMV stably transfected PANC-1 
cell lines were established to reveal the role of 
microRNA-1291 in pancreatic carcinoma cell 
metabolism and suppressed tumorigenesis [3]. It was 
found that stable transfection manipulation induces 
progressive PANC-1 cell senescence, but whether the 
underlying mechanisms of this senescence are 
mitochondrial dysfunction-associated or CPT1C-
depent remain unclear. Therefore, the current study 
aimed to study the metabolomics change in stable 
transfection-induced progressive PANC-1 cell 
senescence and to reveal the underlying molecular 
signals involved in this progress. The metabolomics 
results demonstrate several acylcarnitines and their 
upstream regulatory gene, CPT1C, were strikingly 
decreased in senescent PANC-1 cells. CPT1C was 
further identified as a crucial regulator in stable 
transfection-induced PANC-1 cell senescence by 
inhibiting mitochondrial function-associated metabolic 
reprogramming. These findings suggest the need to 
identify cell culture alterations after stable 
transfection, particularly when cells are used for 
metabolomics and mitochondria-associated studies, 
and suggest inhibition of CPT1C could be a promising 
target to intervene pancreatic tumorigenesis. 
 
RESULTS 
 
Stable transfection-induced PANC-1 cell senescence  
 
In our previous study, microRNA-1291 and its mimic 
empty vector pCMV stably transfected PANC-1 cell 
lines were established to reveal the role of 
microRNA-1291 in pancreatic carcinoma cell 
metabolism and suppressed tumorigenesis [3]. Here, it 
was confirmed that stable transfection of the empty 
vector pCMV in human pancreatic epithelioid 
carcinoma PANC-1 cells led to severe growth arrest 
and cellular senescence. 
 
Vector PANC-1 cells (PANC-1 cells stably transfected 
with the empty vector pCMV were characterized by an 
enlarged and flattened appearance arranged like 
flagstones with increased granularities in the cytoplasm 
(Figure 1A) compared with mock PANC-1 cells 
(untreated PANC-1 cells). Consistent with this result, 
degenerative changes of enlarged nuclei were also 
observed in vector PANC-1 cells (Figure 1B). To 
examine cell growth suppression of the senescence-
associated phenotypes, flow cytometry was performed to 
determine whether stable transfection of the vector 
caused an increase in the population of vector PANC-1 
cells in G2/M phase (Figure 1C). Vector PANC-1 cells 
exhibited lower proliferation than mock PANC-1 cells, as 
revealed by BrdU incorporation measured during DNA 
synthesis (Figure 1D) and cell growth curve tracing 
(Figure 1E). Furthermore, a weaker ability of vector 
PANC-1 cells to form cell colonies was observed (Figure 
1F). IL-8, a key SA secretory phenotype (SASP) factor 
involved in the senescence process [4–7], was increased 
in vector PANC-1 cells compared to mock PANC-1 cells 
(Figure 1G). IL-8 was negatively correlated (but without 
statistical significance) with CPT1C mRNA expression 
in pancreatic cancer patients (Supplementary Figure 2A), 
further supporting enhanced SASP in low-CPT1C-
induced senescent vector PANC-1 cells. More 
importantly, β-galactosidase (SA-β-gal) staining showed 
that mock PANC-1 cells were nearly negative for β-gal, 
while vector PANC-1 cells were positive for senescent 
signals (Figure 1H). The mRNA levels of TNF-α and its 
receptor TNFR1, were significantly increased in vector 
PANC-1, indicating the activation of extrinsic apoptosis 
pathways in the senescent cells. However, FAS mRNA 
expression was reduced in the senescent cells, which 
might result from the negative feedback regulation of 
activation of TNF-α-TNFR1 pathway (Figure 1I). 
 
Taken together, these data indicate that stable 
transfection of the empty vector triggered PANC-1 cells 
into a strong senescence-like growth suppression and 
severe cellular senescence. 
 
Metabolomics reveals a lower level of acylcarnitines 
in senescent vector PANC-1 cells, which is linked to 
reduced CPT1C expression 
 
Metabolomics analysis was performed to further 
identify potential regulators or biomarkers underlying 
cellular senescence induced by stable transfection of the 
empty vector pCMV. To identify the general trends in 
an unbiased way, unsupervised principal component 
analysis (PCA) was performed to reveal differences 
between the mock and vector PANC-1 cells. PCA 
scatter diagrams obtained from HILIC-ESI+-MS (Figure 
2A) and HILIC-ESI--MS (Supplementary Figure 3A) 
showed a clear separation between the mock and vector 
PANC-1 cells, suggesting a distinct discrimination in 
the metabolome profiles between these two groups. S-
plot of OPLS/DA models resulting from HILIC-ESI+- 
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Figure 1. Stable transfection-induced PANC-1 cell senescence. (A) Morphology graph of vector PANC-1 cells. (B) Confocal fluorescent 
graph of the nuclei (blue fluorescence) morphology of vector PANC-1 cells. (C) An increased percentage of vector PANC-1 cells was arrested in 
G2/M phase. Graphic (top) and percentage (bottom) representations of cell cycle distributions are shown. This experiment was repeated 
independently three times. (D) Decreased BrdU incorporation during DNA synthesis in vector PANC-1 cells. Data are presented as the mean ± 
S.E.M, n = 4 (**p < 0.01). (E) Cell growth curve shows decreased proliferation of vector PANC-1 cells. Data are presented as the mean ± S.E.M, 
n = 3 (*p < 0.05, **p < 0.01, ***p < 0.001). (F) Decreased ability of vector PANC-1 cells to form colonies when seeded at the indicated 
dilutions. (G) Quantitative RT-PCR analysis of the upregulated key SASP factor, IL-8 mRNA, in vector PANC-1 cells. Data are presented as the 
mean ± S.E.M, n = 3 (***p < 0.001). (H) SA-β-gal staining and positive senescence signal of vector PANC-1 cells. This experiment was repeated 
independently three times. (I) Activation of extrinsic apoptosis pathways was analyzed. See also Supplementary Figures 1 and 2. 
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MS indicated four significantly changed ions 
(Supplementary Figure 3B). The ions were further 
specifically identified as acetylcarnitine (Supplementary 
Figure 3C), propionylcarnitine (Supplementary Figure 
3D), isobutyrylcarnitine (Supplementary Figure 3E) and 
isovalerylcarnitine (Supplementary Figure 3F). 
Interestingly, the relative response of all of the marker 
ions was significantly reduced in senescent vector 
PANC-1 cells (Figure 2B).  
 
To identify the potential drivers behind the dramatic 
decrease in acylcarnitine levels in senescent vector 
PANC-1 cells, the mRNA expression of genes involved 
in acylcarnitine transport was further determined. 
Specifically, CPT1B and CPT2 mRNA levels were 
significantly decreased in vector PANC-1 cells, while 
CPT1A mRNA levels showed a slight increase and 
carnitine O-acetyltransferase (CRAT) mRNA expression 
remained unchanged (Figure 2C). However, CPT1C 
mRNA levels were the most strikingly decreased in 
vector PANC-1 cells compared to mock PANC-1 cells 
(Figure 2C). Furthermore, CPT1C protein levels were 
significantly reduced in senescent vector PANC-1 cells 
(Figure 2D). Together, these data imply that the 
decrease in CPT1C is the most important contributor to 
the transport of decreased acylcarnitines and may 
represent a driver of vector PANC-1 senescence. 
 
Dysfunctional mitochondria and inhibited telomere 
elongation in low-CPT1C-expressing senescent 
vector PANC-1 cells  
 
CPT1C catalyzes the transportation of fatty acids from 
the cytoplasm to the mitochondrial matrix for β-
oxidation in the mitochondrial outer member. 
Mitochondrial function was further examined in 
senescent vector PANC-1 cells. Notably, vector 
PANC-1 cells produced significantly less ATP under 
conditions of culture medium deprivation (Figure 3A). 
Moreover, the reduced intensity of absorbed rh123 
dye indicated the loss of mitochondrial 
transmembrane permeability upon low CPT1C 
expression in vector PANC-1 cells (Figure 3B).  
 
Oxygen consumption rates (OCRs) from vector PANC-1 
cells exhibited lower maximal respiration after the 
injection of FCCP than mock PANC-1 cells (Figure 3C, 
3D). More importantly, the spare respiratory capacity of 
vector PANC-1 cells was significantly decreased (Figure 
3C, 3E), which was indicative of a reduced ability to 
respond to an increased energy demand. However, vector 
PANC-1 cells also exhibited higher basal respiratory rates 
(Figure 3E) and glycolytic function in the forms of 
extracellular acidification rates (ECARs) (Supplementary 
Figure 4A), implying that the cells may adjust to 
mitochondrial respiration to maintain energy supply 
homeostasis under a long-term stable transfection-induced 
progressive senescence program [8]. Together, partially 
impaired mitochondrial respiration integrity upon low 
CPT1C expression was observed in senescent vector 
PANC-1 cells. 
 
PGC-1a mRNA levels were reduced in vector PANC-1 
cells, and its downstream genes, NRF-1 and TFAM 
mRNAs, were also decreased. CYTB, one of the 
representative mtDNA-encoded subunits [9], was 
subsequently lowered (Figure 3F). 
 
Genes encoding mitochondrial fission and fusion 
proteins, including MFN1, MFN2 and OPA1, were 
significantly reduced in senescent vector PANC-1 cells 
(Figure 3G), suggesting the mitochondrial network 
structure integrity was impaired in the senescent cells, 
which might further explain the impaired mitochondrial 
respiration and mitochondriogenesis pathways. PRNK, 
encoding PARKIN protein, was also reduced, while 
PINK1 mRNA expression increased in the senescent 
cells (Figure 3H). Combined with Figure 3G, these data 
suggested that mitochondrial autophagy (mitophagy) 
process might be hampered and a negative feedback 
might exist.  
 
On the contrary, enhanced cellular bioenergetics 
pathways (Figure 3I) were observed in the senescent 
cells overexpressing CPT1C, which suggested 
mitochondrial function was restored by CPT1C gain-
of-function. 
 
Additionally, the shortening or structural changes of 
telomeres at the ends of the chromosomes leads to a 
DNA damage response and ultimately triggers 
replicative senescence [10]. Shown as Figure 4A, stable 
transfection of the vector pCMV remarkably inhibited 
telomerase activity. As a consequence, the length of the 
telomere in senescent vector PANC-1 cells shortened by 
approximately 0.9 kb (Figure 4B).  
 
Taken together, low CPT1C expression contributed to 
stable transfection-related cell senescence in vector 
PANC-1 cells, which may result from decreased 
mitochondrial function and structure integrity, and 
inhibited telomere elongation in the progressive 
senescence program. On the contrary, mitochondrial 
activity was restored by CPT1C gain-of-function in 
senescent vector PANC-1 cells. 
 
Malignance are reduced in low-CPT1C-expressing 
senescent vector PANC-1 cells 
 
The consequences of mitochondrial dysfunction in 
senescent vector PANC-1 cells with low CPT1C 
expression were further examined. Cells were grown at 
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gradually decreasing concentrations of glucose or 
increasing doses of the glycolysis inhibitor, 2-
deoxyglucose (2-DG), for 72 h; fewer vector PANC-1 
cells were detected in cultures (Supplementary Figure 
5A, 5B). Vector PANC-1 cells also showed higher 
sensitivity to 0.5 mM glucose (Figure 5A), or 20 mM 2-
DG (Figure 5B). More importantly, low CPT1C 
expression sensitized vector PANC-1 cells to rapamycin, 
which is also a source of stress and cytotoxicity, and 
triggered a marked decrease in cell survival in vector 
PANC-1 cells (Figure 5C). These data suggest that low 
CPT1C expression may hinder senescent vector PANC-1 
cell growth under various forms of metabolic stress. 
 
Furthermore, compared with controls, the migration and 
invasion abilities of vector PANC-1 cells were 
significantly reduced (Figure 5D), thus further 
attenuating the incidence of tumor progression arising 
from these cells. Tumors from the senescent vector 
PANC-1 group grew much more slowly and were 
lighter than mock control cells (Figure 5E–5G).  
 
Taken together, low CPT1C expression impaired 
metabolic adaptation and the malignancy of senescent 
vector PANC-1 cells in vitro, which further hindered 
the ability of the transformed cells to form tumors in 
vivo. 
 
Signaling pathways involved in low-CPT1C-
expressing senescent vector PANC-1 cells 
 
Several crucial signaling components that regulate 
mitochondrial function and cellular senescence 
significantly were altered in senescent vector PANC-1 
cells. Specifically, a significant decrease in the mRNAs 
of PPARα, TP53 (P53) and its downstream target gene,
  
 
 
Figure 2. Metabolomics reveals a lower level of acylcarnitines in senescent vector PANC-1 cells, which is linked to reduced 
CPT1C expression. (A) PCA score plots of HILIC-ESI+-MS metabolomics profiles obtained from HILIC-ESI+-MS, n = 6/group. (B) Analysis of the 
relative response of acylcarnitine ions in senescent vector PANC-1 cells. Data are presented as the mean ± S.E.M, n = 6 (***p < 0.001). (C) 
Quantitative RT-PCR analysis of genes related to acylcarnitines. Data are presented as the mean ± S.E.M, n = 3 (ns indicates no significance, *p 
< 0.05, **p < 0.01, ***p < 0.001). The specific human primers to amplify corresponding mRNA were obtained from website of 
http://pga.mgh.harvard.edu/primerbank/ and PrimerDepot, and commercially available (Invitrogen) and shown in Supplementary Table 1. 
(D) Images and densitometric analysis of CPT1C protein bands of senescent vector PANC-1 cells. Data are presented as the mean ± S.E.M, n = 
3 (**p < 0.01). See also Supplementary Figure 3. 
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Figure 3. Dysfunctional mitochondria in low-CPT1C-expressing senescent vector PANC-1 cells. (A) ATP production in senescent 
vector PANC-1 cells, the magnitude of this difference increased as the time in PBS was extended to 24 h. Data are presented as the mean ± 
S.E.M, n = 4 (**p < 0.01, ***p < 0.001). (B) Loss of mitochondrial transmembrane potential measured by the rh123 dequenching method in 
senescent vector PANC-1 cells. Data are presented as the mean ± S.E.M, n = 4 (**p < 0.01). (C) Mitochondrial integrity in the forms of OCRs 
(pMol O2.min-1) in senescent vector PANC-1 cells. Data are presented as the mean ± S.E.M, n = 3. (D) Maximal respiration capacity in the form 
of OCRs in senescent vector PANC-1 cells. Data are presented as the mean ± S.E.M, n = 3 (**p < 0.01). (E) Spare respiratory capacity in the 
form of OCRs in senescent vector PANC-1 cells. Data are presented as the mean ± S.E.M, n = 3 (***p < 0.001). (F) Mitochondriogenesis 
analysis in senescent vector PANC-1 cells. Data are presented as the mean ± S.E.M, n = 3 (*p < 0.05, ***p < 0.001). (G) The mitochondrial 
network structure integrity analysis on the senescent cells. Data are presented as the mean ± S.E.M, n = 3 (***p < 0.001). (H) Mitochondrial 
autophagy analysis on the senescent cells. Data are presented as the mean ± S.E.M, n = 3 (**p < 0.01, ***p < 0.001). (I) Mitochondriogenesis 
analysis on senescent vector PANC-1 cells gaining of CPT1C function. Data are represented as mean ± S.E.M, n = 4 (*p< 0.05). See also 
Supplementary Figure 4. 
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CDKN1A (P21), were observed in senescent vector 
PANC-1 cells (Figure 6A). Reduced protein levels were 
further verified by immunoblotting (Figure 6B). The 
decreased P21 and P16 (Supplementary Figure 6A) 
expression levels also suggested the mitochondrial 
autophagy process was involved in the progressive 
senescence process [11–13]. 
 
The regulation of PPARα on CPT1C was clearly 
illustrated in our previous study [14]. Here, we further 
explored how the transcription factor TP53 regulates 
CPT1C expression. The CPT1C mRNA level was 
upregulated after inducing TP53 mRNA expression 
with 0.7 μM doxorubicin (a positive TP53 agonist) for 
24 h in PANC-1 cells (Figure 6C). CPT1C mRNA also 
increased after over-expressing 2 μg TP53 plasmids for 
24 h in PANC-1 cells (Figure 6D). On the contrary, the 
CPT1C mRNA level was downregulated after 
knockdown of TP53 mRNA expression with 50 μM si-
TP53 for 72 h (Figure 6E). More importantly, 
doxorubicin treatment reversed the si-TP53-induced 
downregulation of CPT1C mRNA expression (Figure 
6F). 
 
Furthermore, CPT1C, a target gene of PPARα [14] and 
TP53 [15], was identified as a novel biomarker and key 
regulator of cancer cell senescence through 
mitochondria-associated metabolic reprogramming [2]. 
PPARα and TP53/CDKN1A are also crucial signaling 
components that regulate mitochondrial function and 
cellular senescence [14, 16]. We further explored the 
connection between CPT1C with PPARα and  
 
TP53/CDKN1A in pancreatic cancer patients 
(Supplementary Figure 7A). According to data from 
Collisson Pancreas cohort, PPARα mRNA level 
positively correlated with CPT1C mRNA expression. 
Both TP53 and CDKN1A mRNA levels had no 
correlation with CPT1C mRNA expression in 
pancreatic cancer patients. 
 
DISCUSSION 
 
Tumor cell lines are widely used experimental models 
for determining the molecular events that drive cell 
growth. However, extended cell culture in vitro 
inevitably triggers culture-related changes of 
phenotypes, including cellular senescence [17, 18]. In 
general, cellular senescence can be divided into 
replicative senescence (RS) and premature senescence. 
RS has been described for all metabolically active cells 
that undergo a spontaneous decline in growth rate [19]. 
Our previous study confirmed that low CPT1C 
expression plays a crucial role in RS and further 
identified CPT1C as a novel biomarker and key 
regulator of cancer cell senescence through 
mitochondria-associated metabolic reprogramming [2]. 
 
Here, PANC-1 cells stably transfected with the empty 
vector, under antibiotic selection with passaging, fell 
into a senescence-like growth suppression and cellular 
senescence process, even without introducing an 
exogenous gene. Metabolomics profiling indicated 
reduced acylcarnitines resulting from the decreased 
expression of their upstream regulatory gene, CPT1C. A 
 
 
 
Figure 4. Inhibited telomere elongation in low-CPT1C-expressing senescent vector PANC-1 cells. (A) Telomerase activity was 
analyzed with the TRAP assay in mock and vector PANC-1 cells. This experiment was repeated three times. (B) Telomere length was 
determined with the TRF length assay in mock and vector PANC-1 cells. 
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decreased CPT1C level caused mitochondrial 
dysfunction, impaired mitochondrial network structure 
integrity, and inhibited telomere elongation, further 
impaired cell survival under metabolic stress, and 
suppressed the malignance and tumorigenesis of 
senescent vector PANC-1 cells. On the contrary, 
mitochondrial activity was restored by CPT1C gain-of-
function in the senescent vector PANC-1 cells. Taken 
together, low CPT1C expression was confirmed to 
cause mitochondria dysfunction -associated metabolic 
reprogramming in senescent vector PANC-1 cells. 
Besides, Lipo2000 reagent was used to establish pCMV 
stably transfected PANC-1 cell line. The lipid 
composition of transfection reagent might get into the 
inner of cells and contribute to the phenotypic changes, 
such as lipid metabolic reprogramming. Stable
 
 
 
Figure 5. Malignance is reduced in low-CPT1C-expressing senescent vector PANC-1 cells. Sensitivity to metabolic stress from (A) 
glucose deprivation (0.5 mM glucose) and (B) glycolytic inhibition (20 mM 2-deoxyglucose) of senescent vector PANC-1 cells at the indicated 
time points. Data are presented as the mean ± S.E.M, n = 5 (*p < 0.05, **p < 0.01, ***p < 0.001). (C) Sensitivity to metabolic stress from 
rapamycin stimuli of senescent vector PANC-1 cells at the indicated concentrations. Data are presented as the mean ± S.E.M, n = 5 (**p < 
0.01, ***p < 0.001). (D) Transwell migration and Matrigel invasion capacities of senescent vector PANC-1 cells. Data are presented as the 
mean ± S.E.M, n = 3 (*p < 0.05, **p < 0.01). (E) Tumor sizes are presented as the mean ± S.E.M over time, (n = 5) (**p < 0.01, ***p < 0.001). 
(F) Images of tumors after excision on day 42 post-implantation. (G) Comparison of dissected tumor weights (mean ± S.E.M, ***p < 0.001). 
See also Supplementary Figure 5. 
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Figure 6. Signaling pathways involved in low-CPT1C-expression-induced senescence in vector PANC-1 cells and regulation of the 
TP53 signaling pathway on CPT1C. (A) Quantitative RT-PCR analysis for suppressed genes in senescent vector PANC-1 cells. Data are 
presented as the mean ± S.E.M, n = 3 (***p < 0.001). (B) Images and densitometric analysis for protein bands altered in senescent vector PANC-1 
cells. The left panel shared the same GAPDH control with Figure 2D, all these bands were harvested from the same experiment. Data are 
presented as the mean ± S.E.M, n = 3 (*p < 0.05, **p < 0.01, ***p < 0.001). (C) The CPT1C mRNA level is upregulated after inducing TP53 mRNA 
expression with 0.7 μM doxorubicin (Sigma) for 24 h in PANC-1 cells. (D) CPT1C mRNA is increased after overexpressing 2 μg of TP53 plasmids for 
24 h in PANC-1 cells. (E) CPT1C mRNA expression was downregulated after knockdown of TP53 mRNA expression with 50 μM si-TP53 for 72 h in 
PANC-1 cells. The sequences of specific human siRNAs were commercially available (RiboBio) and listed in Supplementary Table 2. The optimal 
sense against TP53 was the following: 5`-GCACAGAGGAAGAGAAUCU dTdT-3'. (F) Doxorubicin reversed the si-TP53-induced downregulation of 
CPT1C mRNA expression. For the statistical analysis of TP53 mRNA expression, 1 si-Control+Doxorubicin vs si-Control+DMSO, ***p < 0.001; 2 si-
TP53+DMSO vs si-Control+DMSO, ***p < 0.001; and 3 si-TP53+Doxorubicin vs si-TP53+DMSO, **p < 0.01. For the statistical analysis of 
CDKN1A/P53 mRNA level, 4 si-Control+Doxorubicin vs si-Control+DMSO, ***p < 0.001; 5 si-TP53+DMSO vs si-Control+DMSO, *p < 0.05; and 6 si-
TP53+Doxorubicin vs si-TP53+DMSO, **p < 0.01. For the statistical analysis of CPT1C mRNA expression, 7 si-Control+Doxorubicin vs si-
Control+DMSO, ***p < 0.001; 8 si-TP53+DMSO vs si-Control+DMSO, *p < 0.05; and 9 si-TP53+Doxorubicin vs si-TP53+DMSO, **p < 0.01. See also 
Supplementary Figure 7. 
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transfection manipulation-induced progressive 
senescence provided further evidence to our previous 
study that low a CPT1C level plays a crucial role in the 
mitochondrial dysfunction and metabolic 
reprogramming-associated RS process [2].  
 
Mounting evidence suggests that aberrant mitochondria 
trigger cellular senescence [20–22]. In our previous 
study, mitochondrial dysfunction-mediated senescent 
phenotypes were observed when CPT1C was efficiently 
depleted in tumor cell lines. Conversely, CPT1C gain-
of-function reversed impaired mitochondrial function 
and cellular senescence [2]. Deregulation of lipid 
metabolism was reported to induce senescence process 
[23], which was further confirmed by our previous 
study that accumulated lipids and lipid toxicity induced 
cellular senescence [24]. In the current study, a 
decreased CPT1C level caused mitochondrial 
dysfunction and impaired mitochondrial structure 
integrity on senescent vector PANC-1 cells, further 
supporting that the absence of CPT1C contributes to 
mitochondrial dysfunction-related cellular senescence. 
Down-regulation of mitochondrial fission and fusion 
genes [25] and the PINK1/PARKIN pathway [26], and 
the decreased P21 and P16 mRNA expression [13, 27], 
suggested that impaired mitochondrial autophagy 
process might be induced in senescent cells with low 
CPT1C expression [28]. On the contrary, mitochondrial 
activity was restored by CPT1C gain-of-function in 
senescent cells. Moreover, several well-characterized 
triggers of senescence were identified, including 
shortened telomeres, activated oncogenes, and 
genotoxic and oxidative stress [10, 29]. RS results 
primarily from the shortening and other structural 
changes of telomeres at the ends of chromosomes and 
further triggers the DNA damage response [10]. Here, 
we demonstrated that stable transfection with the vector 
pCMV remarkably inhibited telomerase activity and 
further depressed telomerase activity-catalyzed telomere 
elongation in senescent vector PANC-1 cells with low 
CPT1C expression. 
 
The suppression of proliferation of senescent cells, to a 
large degree, is mediated by cyclin-dependent kinase 
inhibitor p21WAF1 and the tumor suppressor p53 
pathway [30, 31]. Depletion of the novel p53 target 
gene, cpt1c, delays tumor growth in the 
neurofibromatosis type I tumor model [15]. Hence, we 
speculated that CPT1C regulates cellular senescence via 
its upstream gene, TP53. Here, decreased expression of 
TP53 and its downstream target gene CDKN1A/P21 
was observed in senescent vector PANC-1 cells, 
supporting the crucial role of the TP53/CDKN1A 
pathway in regulating cellular senescence. Moreover, 
our previous study demonstrated that PPARα regulates 
cellular senescence by its novel target gene, CPT1C 
[14]. Here, PPARα expression was downregulated in 
senescent PANC-1 cells. In pancreatic cancer patients, 
the PPARα mRNA level positively correlated with 
CPT1C mRNA expression, while both TP53 and 
CDKN1A mRNA levels had no correlation with CPT1C 
mRNA expression. CDKN1A/P21 is a  
well-known inhibitor of cell cycle and can arrest the 
DNA damage-induced cell cycle progression in G1/S 
and G2/M transitions by inhibiting mitotic CDK4, 
6/cyclin-D and CDK2/cyclin-E complexes, respectively 
[13]. Our data also showed increased G2/M phase arrest 
in the population of vector PANC-1 cells with 
senescence phenotypes and low CPT1C expression. 
TP53-P21 pathway plays a prominent pro-apoptotic 
role, while reversely it also promotes tumor cell 
survival in response to metabolic stress [15]. The two-
sided effects of TP53-P21 pathway may explain the 
decrease in TP53, P21 and CPT1C in senescent vector 
PANC-1 cells. Feedback regulation for cells to maintain 
homeostasis status in the progressive senescence 
program, may explain no correlation between TP53/P21 
levels and CPT1C expression. 
 
CPT1C, an enzyme located in the outer mitochondrial 
membrane [32], is involved in lipid metabolism, cellular 
energy supply [33–35] and other physiological or 
pathological processes [36–39]. The knockdown of 
CPT1C inhibited the tumorigenesis of PANC-1 cells in 
vivo [2, 33] and further suppressed xenograft tumor 
growth in situ [2], suggesting that CPT1C represents a 
therapeutic target for cancer treatment. In summary, 
stable transfection-induced progressive PANC-1 cell 
senescence is involved in decreased CPT1C expression 
through the collapse of mitochondrial function-
associated metabolic reprogramming. These results 
confirm the need to identify cell culture alterations after 
stable transfection, particularly when used for 
metabolomics and mitochondria-associated studies, and 
further suggest that inhibition of CPT1C has the 
potential to be a target to intervene pancreatic 
tumorigenesis. 
 
MATERIALS AND METHODS  
 
Cell culture 
 
PANC-1 cell line was purchased and authenticated with 
STR genotyping from Guangzhou Cellcook Biotech 
Co., Ltd., and further verified without mycoplasma 
contamination (Beyotime).  
 
Cells were grown in the Dulbecco's modified Eagle's 
medium (DMEM, Cellgro) with 10% fetal bovine serum 
(FBS, Gibco), 100 U/mL penicillin sodium (Lonza) and 
100 μg/mL streptomycin sulfate (Lonza) at 37 °C in a 
humidified atmosphere with 5% CO2. 
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Establishment of pCMV stably transfected PANC-1 
cell line 
 
As shown in our previous study [40], 2 × 105 PANC-1 
cells in exponential growth were seeded into a well of a 
6-well plate. After 24 hours, cells were transfected with 
2.5 mg of pCMV empty vector with a selectable marker 
using Lipo2000 (Invitrogen). Culture media was 
replaced after 24 hours, then cells were selected with 
500 mg/mL G418. After 3~5 weeks, G418-resistant 
clones were selected with a cloning ring for 
amplification in further culture.  
 
Senescence-like growth suppression and cellular 
senescence analysis 
 
Cell morphology photographs were taken by a 
microscope (×200, Olympus). Cells plated onto 
coverslip (NEST) were fixed with 4% 
paraformaldehyde, cell nuclei were stained with 
ProLong Gold Antifade Reagent with DAPI 
(Invitrogen), the cell nuclei morphology was then 
observed with a laser confocal microscope (Zeiss). Cells 
fixed in cold 70% ethanol overnight were stained with 
propidium iodide (PI, Beyotime) staining buffer in the 
dark at 37 °C for 30 min, cell cycle was then analyzed 
on an EPICS XL flow cytometer (Beckman Coulter). 
Cells were labeled with 5-bromo-29-deoxyuridine 
(BrdU) for 72 h, then fixed in situ and incubated with 
anti-BrdU antibodies for 90 min. Rinsing with PBS, 
cells were incubated with substrate solution for 5 min. 
The absorbance was measured at 370 nm with a 
reference wavelength at 492 nm [41]. A cell growth 
curve was also drawn to observe the cell growth rate. 
Cells were seeded into 6-well plates at a density of 1 × 
105 cells/well, cultured under standard culture 
conditions, and counted under a microscope with trypan 
blue on the indicated days. 5000, 2500 or 1250 cells 
were cultured for 2 weeks, then fixed and stained with 
Diff-Quik (Propbs), colony areas were quantified with 
ImageJ software to investigate colony formation ability. 
The induction of IL-8 mRNA expression was analyzed 
by quantitative RT-PCR to evaluate SASP as previously 
reported [7]. The SA-β-gal assay (Beyotime) is the most 
commonly used method to detect senescent cells [42]. 
Cells were fixed and stained with staining working 
solution containing X-Gal at 37 °C overnight, the 
population of SA-β-gal positive cells was then counted. 
 
Apoptosis pathway analysis 
 
For apoptosis pathway analysis, the TNF-α, TNFR1 and 
Fas mRNA expression was analyzed by quantitative 
RT-PCR [43].  
Metabolomics analysis 
 
The collection, preparation and UPLC-ESI-QE-MS 
analysis on the cell sample for metabolomics were 
performed as described in our previous reports [3, 44]. 
An aliquot (5 μL) of samples were subjected to an ultra-
high performance liquid chromatography electrospray 
ionization mass spectrometry (UHPLC-ESI-MS). 
Hydrophilic interaction chromatography (HILIC) 
separation was performed with an Atlantis Silica HILIC 
column (3 μm, 2.1 mm i.d. × 100 mm, Waters) on a 
Thermo Scientific Dionex Ultimate 3000 UHPLC 
system. MS was performed with a Thermo Scientific Q 
ExactiveTM benchtop Orbitrap mass spectrometer in 
ESI positive or negative mode (Thermo Scientific). 
Untargeted profiling analysis acquired the data followed 
by Top-10 data-dependent MS/MS. Total ion 
chromatograms and mass spectra from LC-HRMS runs 
were generated as raw files in Xcalibur (Thermo 
Scientific). 
 
Optimization for comprehensive metabolite phenotypes 
between two groups and discovering differential 
metabolites, data mining consisting of background noise 
subtraction, automated peak detection and integration, 
peak alignment, multivariate principal component 
analysis (PCA) and univariate analysis, were performed 
with Thermo Scientific label-free differential analysis 
bioinformatics software SIEVE 2.2 (Thermo Scientific) 
and SIMCA-P 13.0 (Umetrics). Subsequently, 
metabolites were putatively identified based on accurate 
mass match and fragmentation pattern match. With the 
mass-to-charge (m/z) ratio of the metabolic features, 
putative structural annotation was carried out by 
retrieving the metabolite databases HMDB 
(http://www.hmdb.ca/), KEGG (http://www.genome.jp/ 
kegg/) and METLIN (http://metlin.scripps.edu). Mz 
Cloud (https://www.mzcloud.org/) and METLIN were 
used to match MS/MS spectral.  
 
Quantitative RT-PCR analysis 
 
Analysis was performed as described in a previous 
report [45]. Cells were lysed with Trizol (Invitrogen), 
and total RNA was extracted with ethanol precipitation. 
RNA concentration was measured with a NanoDrop 
Flex Station 3 (Molecular Device). 1 μg purified RNA 
was  randomly reverse-transcribed to cDNA with the 
PrimeScript RT reagent kit with gDNA eraser (TaKaRa 
Biotech). Real-time PCR was then performed with 
SYBR Premix Ex Taq II (Tli RnaseH Plus) kit (TaKaRa 
Biotech) in a 7500 Real-Time PCR System (Applied 
Biosystems). Raw gene expression values were 
normalized with housekeeping ACTB mRNA from  
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the same reaction. The specific human primers  
obtained from website of http://pga.mgh.harvard.edu/ 
primerbank/ and PrimerDepot, were commercially 
available at Invitrogen Corporation and shown in 
Supplementary Table 1. 
 
Western blot analysis 
 
Analysis was performed as described in a previous report 
[46]. Cells were homogenized with the 
Radioimmunoprecipitation assay (RIPA) lysis buffer 
containing phenylmethylsulfonyl fluoride (PMSF). 
Concentrations of prepared proteins were determined 
with the BCA protein assay (Thermo Scientific). Proteins 
were electrophoresed with a 10% SDS-PAGE and 
transferred to the Polyvinylidene Fluoride (PVDF) 
membranes (Millipore). 5% nonfat milk in Tris-Buffered-
Saline with Tween (TBST) was used to block the 
nonspecific banding, then PVDF membranes were 
incubated with primary antibody overnight at 4°C. The 
antibodies used were: CPT1C (Cat. No.: #ab87498, 
Abcam), TP53 (#ab26, Abcam), P21 (#sc-271610, Santa 
Cruz), PPARα (#ab24509, Abcam) and GAPDH (#2118, 
Cell Signaling Technology). The immunoblot bands were 
visualized by anti-rabbit horseradish peroxidase-linked 
secondary antibody (Cell Signaling Technology) for 1 h 
at 37°C. After washing with TBST for 3 times, protein-
antibody complexes were detected with the 
Electrochemiluminescence (ECL) detection kit (Engreen 
Biosystem) on a chemiluminescence imaging system (GE 
Healthcare). The intensity of immunoblot bands was 
quantitated with the Quantity One software (Bio-Rad 
Laboratories). 
 
Mitochondrial dysfunction analysis 
 
Analysis was performed as described in our previous 
study [2]. To measure the total ATP production, culture 
medium was replaced with PBS for 12 h and 
luminescence representing cellular ATP production 
levels was detected with the CellTiter-Glo Luminescent 
Cell Viability Assay (Promega) on a FlexStation 3 
(Molecular Devices). The mitochondrial membrane 
depolarization was measured via fluorescence 
dequenching of 0.4 μM rh123 (Sigma) as previously 
reported [47]. The mean rh123 (excitation: 485 nm, 
emission: 535 nm) fluorescent intensity of 25 fields in 
each well was calculated with ArrayScanVTI High 
Content Application (Thermo Fisher). Cells were seeded 
into XF24 V7 cell culture plates (Seahorse Bioscience) 
with the same cell density to analyze mitochondrial 
respirations between the two groups as previously 
described [48]. The culture medium was replaced with 
XF assay medium (Seahorse Bioscience) on the next day. 
After incubation without CO2 for 1 h, the rate of change 
for dissolved O2 concentration (measurement of OCR) 
was measured by an XF24 Extracellular Flux Analyzer 
(Seahorse Bioscience). Cells were incubated under four 
conditions sequentially: (a) basal respiration was 
measured without additives; (b) 1 μM oligomycin was 
added to inhibit ATP synthase, mitochondrial Complex V 
and oxidative phosphorylation (OXPHOS); (c) the 
maximal mitochondrial respiration was induced by 
adding 1 μM carbonyl cyanide-4-trifluoro methoxy 
phenyl hydrazine (FCCP, a mitochondrial uncoupler); 
and (d) the reaction was ended with 1 μM rotenone and 1 
μM antimycin A (mitochondrial Complex I and III 
inhibitors and poisons). Considering the size of senescent 
vector PANC-1 cells was larger than the untreated 
PANC-1 cells, the mitochondrial respiration OCRs were 
normalized with the total protein concentration of each 
group after harvesting and lysing the cells for the 
Seahorse experiment. Mitochondrial respirations coupled 
to ATP synthesis were obtained with subtracting 
oligomycin responses from the basal OCRs. The 
difference between maximal respirations and basal 
respirations was defined as spare respiratory capacity. 
Mitochondriogenic pathways and mitochondrial-encoded 
mRNAs were measured via quantitative RT-PCR 
analysis as previously described. For analysis of the 
integrity of the mitochondrial network, the MFN1, MFN2 
and OPA1 levels were measured by quantitative RT-PCR 
[25]. Mitophagy was analyzed for the MFN1, MFN2 and 
OPA1 levels and PINK1/PARKIN pathway using 
quantitative RT-PCR [26]. 
 
Telomerase activity and telomere length assays 
 
Telomerase activity analysis was performed with a 
telomeric repeat amplification protocol (TRAP) assay. 
Briefly, approximately 2 × 106 cells were resuspended in 
lysis reagent. Telomeric DNA was elongated and purified, 
and amplification was performed by PCR. PCR products 
were separated on a 10% nondenaturing PAGE gel. The 
gel was fixed, stained using Gel-red (Biotium) and 
photographed. The terminal restriction fragment (TRF) 
length assay was performed to determine the telomere 
length as described in a previous report [41, 49]. Genomic 
DNA was digested with Hinf1/Rsal restriction enzymes. 
The digested DNA fragments were electrophoresed on a 
0.8% agarose gel, transferred to a nylon membrane by 
capillary transfer and then fixed on a wet blotting 
membrane by UV crosslinking. The membrane  
was hybridized with a DIG-labeled hybridization probe 
for telomeric repeats and incubated with anti-DIG-
alkaline phosphatase. The TRF was determined by 
chemiluminescence detection (GE Healthcare). 
 
Metabolic stress stimuli  
 
Analysis was performed as previously described [50]. 
The cells were incubated in culture medium deprived of 
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glucose (Sigma). 2-DG (Sigma) in PBS was diluted to 
the required concentrations with culture medium. Cells 
were further treated with pre-optimized 0.5 mM glucose 
or 20 mM 2-DG at the indicated days. Rapamycin 
(Chemietek) in DMSO was diluted to the indicated 
concentrations with culture media, SRB staining was 
performed to evaluate the cell growth after 72 h. 
 
Sulforhodamine B (SRB) assays 
 
Analysis was performed as previously described [51]. 
Cells were fixed in situ with 50 μL of pre-cold 50% 
(w/v) trichloroacetic acid (TCA) for 1 h at 4°C. After 
washing with ultrapure water and drying, each well was 
incubated in 100 μL of 0.4% SRB solution (w/v, SRB 
dissolved in 1% (v/v) acetic acid) for 30 min at room 
temperature. After washing with 1% acetic acid and 
drying, SRB stains were solubilized in 10 mM Tris-HCl 
(pH=10.5) and absorbance was determined at 515 nm. 
 
Transwell migration and matrigel invasion assays 
 
Assays were employed as described in our previous 
reports [3, 50]. Transwell migration and matrigel 
invasion assays were employed to evaluate cell migration 
and invasion capacities, respectively. Briefly, cells 
suspension of 3×104 was added to cell culture inserts 
(Corning) containing a polycarbonate filter with 8 μm 
diameter pores blocked with 2.5% BSA for transwell 
migration assay or coated with 1:5 dilution matrigel 100 
ul/well for matrigel invasion assay. Cells were incubated 
for 17 h under standard culture conditions. Tumor cells 
remaining on the topside of the membrane or gel were 
removed, and cells that had migrated or invaded to the 
underside were fixed and stained with Diff-Quik 
(PolySciences). Five fields per insert were photographed 
and the number of cells was counted under microscope. 
 
Xenograft mice assays  
 
Mouse xenograft model were used as previously 
described [3]. 6~8 weeks old athymic male nude mice 
(BALB/c-nu/nu) were purchased from the Laboratory 
Animal Center of Sun Yat-sen University, and 
maintained with water and chow provided ad libitum 
under standard 12 h light/ 12 h dark cycle. Exponentially-
growing cells were injected subcutaneously into the right 
flank of mice (5 × 106 cells in 0.2 ml of 50% matrigel 
basement membrane matrix (BD Biosciences) per 
mouse). Tumor sizes and body weights were measured 
once a week for 6 weeks, tumor length and width were 
measured with a digital caliper. The formula utilized to 
calculate was: tumor volume (mm3) = 3.14/6*((tumor 
length + width)/2)^3. Mice were sacrificed when the 
tumors reached 2 cm in diameter, and xenograft tumors 
were extracted and weighed. 
Bioinformatics analysis 
 
All cohort data were downloaded at https://www. 
oncomine.org [52] and http://www.cbioportal.org [53, 
54]. The CPT1C reporter (probe) is 227468_at, the 
PPARα reporter is 206870_at, the TP53 reporter is 
201746_at, the CDKN1A reporter is 1555186_at, the IL-8 
reporter is 202859_x_at in Collisson Pancreas cohort  
(n = 27). 
 
Plasmid transit transfection  
 
Analysis was performed as described in a previous 
report [55]. Human CPT1C expression plasmid was 
commercially constructed by Genechem Corporation. 
Human TP53 expression plasmid was obtained from 
Addgene nonprofit plasmid repository. Briefly, the cells 
were grown in 6-well plates at 80% confluence then 
transfected with plasmids using Lipo2000 reagent 
(Invitrogen) in antibiotic-free culture medium following 
the instruction of manufacturer. More detailed, 4 μL 
Lipo2000 reagent or 2 μg DNA was diluted well in 250 
μL Opti-MEM medium then incubated for 5 mins 
respectively. 250 μL diluted DNA was added to 250 μL 
diluted Lipo2000 reagent (1:1 ratio) then incubated for 
20 mins. 500 μL DNA-reagent complex was added to 
the culture medium of each well and mixed gently. 
Quantitative RT-PCR was performed at 24 h post-
transfection as described above. 
 
Gene silencing by RNA interference  
 
Silencing with siRNA was performed as previously 
described [56]. Cells were seeded into 6-well plates at 1 
× 105 cells/well. Cells were transfected with 50 nM 
siRNA or siControl using the Lipofectamine 
RNAiMAX (Life Technologies) on the second day. 
Quantitative RT-PCR was performed at 72 h post-
transfection as described above. The sequences of 
specific human siRNAs were commercially available 
(RiboBio) and listed in Supplementary Table 2.  
 
Statistical analysis 
 
All values were expressed as the mean ± S.E.M. Two-
tailed Student’s t tests and graphs were performed using 
GraphPad Prism v6.0c software. Significance is 
represented by *p < 0.05, **p < 0.01, **p < 0.001 
versus control. 
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SUPPLEMENTARY MATERIALS 
 
Supplementary Figures 
 
 
 
 
 
Supplementary Figure 1. (related to Figure 1). Quantification of the cell nuclei size. (A) The cell nuclei size was quantified with 
Image J software. 
. 
 
 
 
 
 
Supplementary Figure 2. (related to Figure 1). Correlation of key SASP factor, IL-8 with CPT1C expression in pancreatic cancer 
patients. (A) IL-8 negatively correlates with CPT1C mRNA expression in pancreatic cancer patients. 
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Supplementary Figure 3. (related to Figure 2). Metabolomics profiles reveal significantly decreased acylcarnitines in 
senescent vector PANC-1 cells. (A) PCA score plots of HILIC-ESI--MS metabolomics profiles obtained from HILIC-ESI--MS, n = 6/group. (B) 
S-plot of OPLS/DA models of HILIC-ESI+-MS data. (C–F) Validation of cell metabolite biomarkers by LC-MS/MS analysis. Corresponding MS/MS 
spectra of authentic chemicals (up) and cell samples (bottom) are shown. 
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Supplementary Figure 4. (related to Figure 3). Vector PANC-1 cells exhibited higher glycolytic function. (A) Glycolytic function in 
the forms of ECARs (mpH.min-1) in senescent vector PANC-1 cells. Data are presented as the mean ± S.E.M, n = 3. 
 
 
 
Supplementary Figure 5. (related to Figure 5). Cell sensitivity to metabolic stress. Cell sensitivity to metabolic stress from (A) 
glucose withdrawal and (B) glycolytic inhibition in senescent vector PANC-1 cells at the indicated concentrations is shown. Data are presented 
as the mean ± S.E.M, n = 5 (*p < 0.05, **p < 0.01). 
 
 
 
Supplementary Figure 6. Reduced CDKN1A (P16) mRNA in the senescent vector PANC-1 cells. (A) Quantitative RT-PCR analysis for 
P16 was performed in the senescent vector PANC-1 cells. 
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Supplementary Figure 7. (related to Figure 6). Correlation of crucial signaling components of cellular senescence with CPT1C 
expression in pancreatic cancer patients. (A) Correlation analysis between PPARα, TP53, and CDKN1A with CPT1C mRNA expression in 
pancreatic cancer patients (data from the Collisson Pancreas cohort, n = 27). 
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Supplementary Tables 
 
Supplementary Table 1. Sequence of primers for quantitative RT-PCR analysis. 
Gene  
Name 
Genebank  
Accession 
Species 
Specificity 
Sequences  
of Primers 
β-actin NM_001101 Human forward 5′- CCTTGCACATGCCGGAG-3′ 
reverse 5′-GCACAGAGCCTCGCCTT-3′ 
CPT1A NM_001876 Human forward 5′-GCCTCGTATGTGAGGCAAAA-3′ 
reverse 5′-TCATCAAGAAATGTCGCACG-3′ 
CPT1B NM_004377 Human forward 5′-GGTCCAGTTTACGGCGATAC-3′ 
reverse 5′-CCTCTCATGGTGAACAGCAA-3′ 
CPT1C NM_001136052 Human forward 5′-GGATGGCACTGAAGAGGAAA-3′ 
reverse 5′-TCCTGGAAAAGGCATCTCTC-3′ 
CPT2 NM_000098 Human forward 5′-CGGAGTCTCGAGCAGATAGG-3′ 
reverse 5′- GGAAAAGAACTGCATGAGCA-3′ 
CRAT NM_001257363 Human forward 5′-GGGCTCGAGTAGATGACCAC-3′ 
reverse 5′-ATGAGTTTCAGGCCTCAGGA-3′ 
IL-8 NM_000584 Human forward 5′- ACTGAGAGTGATTGAGAGTGGAC-3′ 
reverse 5′-AACCCTCTGCACCCAGTTTTC-3′ 
PGC-1α NM_013261 Human forward 5′-AATCCGTCTTCATCCACAGG-3′ 
reverse 5′-GGTGCAGTGACCAATCAGAA-3′ 
NRF1 NM_001040110 Human forward 5′-AGGAACACGGAGTGACCCAA-3′ 
reverse 5′-TATGCTCGGTGTAAGTAGCCA-3′ 
TFAM NM_003201 Human forward 5′- ATGGCGTTTCTCCGAAGCAT-3′ 
reverse 5′-TCCGCCCTATAAGCATCTTGA-3′ 
Cytochrome b NM_000101 Human forward 5′-CCCAGTGGTACTTTGGTGCC-3′ 
reverse 5′-GCGGTCATGTACTTCTGTCCC-3′ 
TP53 NM_001126118 Human forward 5′-CAGCACATGACGGAGGTTGT-3′ 
reverse 5′-TCATCCAAATACTCCACACGC-3′ 
CDKN1A NM_078467 Human forward 5′-TGTCCGTCAGAACCCATGC-3′ 
reverse 5′-AAAGTCGAAGTTCCATCGCTC-3′ 
PPARα NM_005036 Human forward 5′-CGGTGACTTATCCTGTGGTCC-3′ 
reverse 5′-CCGCAGATTCTACATTCGATGTT-3′ 
TNFA NM_000594 Human forward 5′-GAGGCCAAGCCCTGGTATG-3′ 
reverse 5′-CGGGCCGATTGATCTCAGC-3′ 
TNFR1 NM_001065 Human forward 5′-AACGAGTGTGTCTCCTGTAGT-3′ 
reverse 5′-GGAGTAGAGCTTGGACTTCCAC-3′ 
FAS NM_000043 Human forward 5′-AGATTGTGTGATGAAGGACATGG-3′ 
reverse 5′-TGTTGCTGGTGAGTGTGCATT-3′ 
FASL NM_000639 Human forward 5′-TGCCTTGGTAGGATTGGGC-3′ 
reverse 5′-GCTGGTAGACTCTCGGAGTTC-3′ 
PRKN NM_004562 Human forward 5′-CCCACCTCTGACAAGGAAACA-3′ 
reverse 5′-TCGTGAACAAACTGCCGATCA-3′ 
PINK1 NM_032409 Human forward 5′-GGAGGAGTATCTGATAGGGCAG-3′ 
reverse 5′-AACCCGGTGCTCTTTGTCAC-3′ 
CDKN2A NM_000077 Human forward 5′-ATGGAGCCTTCGGCTGACT-3′ 
reverse 5′-GTAACTATTCGGTGCGTTGGG-3′ 
OPA1 NM_015560 Human forward 5′-CTGCAGGTCCCAAATTGGTT-3′ 
reverse 5′-TCTTTGTCTGACACCTTCCTGT-3′ 
MFN1 NM_033540 Human forward 5′-CGGGGTGACCTTCGAGC-3′ 
reverse 5′-TTCTGCCATTATGCACCTGGA-3′ 
MFN2 NM_001127660 Human forward 5′-AGCGTTCAGAGGCCATCG-3′ 
reverse 5′-TCCAAGCTTCTTCACCTTCCC-3′ 
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Supplementary Table 2. Sequences of RNAi assay. 
RNAi Name Species Specificity Sequences 
siRNA TP53-1 Human 5′-GGACAUACCAGCUUAGAUU dTdT-3′ 
siRNA TP53-2 Human 5′-GCACAGAGGAAGAGAAUCU dTdT-3′ 
siRNA TP53-3 Human 5′-GACUCCAGUGGUAAUCUAC dTdT-3′ 
 
 
